Extrapancreatic effects of GIP and GLP-1

Adrian Vella, R. A. Rizza

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Incretin-based therapy promises to be a useful adjunct in the treatment of diabetes. Glucagon-like peptide-1 (GLP1) and, to a lesser extent, glucose-dependent insulinotropic polypeptide (GIP) are potent stimulators of insulin secretion, and consequently have significant effects on the regulation of the glucose metabolism. What has been less clear, however, is whether these hormones exert direct effects on glucose metabolism independent of their effect on pancreatic insulin and glucagon release. Glucose effectiveness and insulin action (the ability of glucose and insulin respectively to stimulate glucose uptake and suppress glucose release) have been reported by some investigators, but not others, to improve during incretin infusion. The purpose of this review is briefly to examine some of the numerous conflicting reports in the literature as to the presence or otherwise of extrapancreatic incretin effects. In addition, we will briefly discuss the gastrointestinal effects of incretins. These effects may be of considerable importance in the treatment of postprandial hyperglycemia although they are not, strictly speaking, the result of a direct incretin effect on glucose metabolism.

Original languageEnglish (US)
Pages (from-to)830-836
Number of pages7
JournalHormone and Metabolic Research
Volume36
Issue number11-12
DOIs
StatePublished - Nov 2004

Fingerprint

Glucagon-Like Peptide 1
Incretins
Glucose
Peptides
Metabolism
Insulin
Medical problems
Glucagon
Hyperglycemia
Research Personnel
Hormones

Keywords

  • Glucose effectiveness
  • Incretins
  • Insulin action

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Extrapancreatic effects of GIP and GLP-1. / Vella, Adrian; Rizza, R. A.

In: Hormone and Metabolic Research, Vol. 36, No. 11-12, 11.2004, p. 830-836.

Research output: Contribution to journalArticle

Vella, Adrian ; Rizza, R. A. / Extrapancreatic effects of GIP and GLP-1. In: Hormone and Metabolic Research. 2004 ; Vol. 36, No. 11-12. pp. 830-836.
@article{ad7bd24897a447bc86f7f6686173b346,
title = "Extrapancreatic effects of GIP and GLP-1",
abstract = "Incretin-based therapy promises to be a useful adjunct in the treatment of diabetes. Glucagon-like peptide-1 (GLP1) and, to a lesser extent, glucose-dependent insulinotropic polypeptide (GIP) are potent stimulators of insulin secretion, and consequently have significant effects on the regulation of the glucose metabolism. What has been less clear, however, is whether these hormones exert direct effects on glucose metabolism independent of their effect on pancreatic insulin and glucagon release. Glucose effectiveness and insulin action (the ability of glucose and insulin respectively to stimulate glucose uptake and suppress glucose release) have been reported by some investigators, but not others, to improve during incretin infusion. The purpose of this review is briefly to examine some of the numerous conflicting reports in the literature as to the presence or otherwise of extrapancreatic incretin effects. In addition, we will briefly discuss the gastrointestinal effects of incretins. These effects may be of considerable importance in the treatment of postprandial hyperglycemia although they are not, strictly speaking, the result of a direct incretin effect on glucose metabolism.",
keywords = "Glucose effectiveness, Incretins, Insulin action",
author = "Adrian Vella and Rizza, {R. A.}",
year = "2004",
month = "11",
doi = "10.1055/s-2004-82617",
language = "English (US)",
volume = "36",
pages = "830--836",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "11-12",

}

TY - JOUR

T1 - Extrapancreatic effects of GIP and GLP-1

AU - Vella, Adrian

AU - Rizza, R. A.

PY - 2004/11

Y1 - 2004/11

N2 - Incretin-based therapy promises to be a useful adjunct in the treatment of diabetes. Glucagon-like peptide-1 (GLP1) and, to a lesser extent, glucose-dependent insulinotropic polypeptide (GIP) are potent stimulators of insulin secretion, and consequently have significant effects on the regulation of the glucose metabolism. What has been less clear, however, is whether these hormones exert direct effects on glucose metabolism independent of their effect on pancreatic insulin and glucagon release. Glucose effectiveness and insulin action (the ability of glucose and insulin respectively to stimulate glucose uptake and suppress glucose release) have been reported by some investigators, but not others, to improve during incretin infusion. The purpose of this review is briefly to examine some of the numerous conflicting reports in the literature as to the presence or otherwise of extrapancreatic incretin effects. In addition, we will briefly discuss the gastrointestinal effects of incretins. These effects may be of considerable importance in the treatment of postprandial hyperglycemia although they are not, strictly speaking, the result of a direct incretin effect on glucose metabolism.

AB - Incretin-based therapy promises to be a useful adjunct in the treatment of diabetes. Glucagon-like peptide-1 (GLP1) and, to a lesser extent, glucose-dependent insulinotropic polypeptide (GIP) are potent stimulators of insulin secretion, and consequently have significant effects on the regulation of the glucose metabolism. What has been less clear, however, is whether these hormones exert direct effects on glucose metabolism independent of their effect on pancreatic insulin and glucagon release. Glucose effectiveness and insulin action (the ability of glucose and insulin respectively to stimulate glucose uptake and suppress glucose release) have been reported by some investigators, but not others, to improve during incretin infusion. The purpose of this review is briefly to examine some of the numerous conflicting reports in the literature as to the presence or otherwise of extrapancreatic incretin effects. In addition, we will briefly discuss the gastrointestinal effects of incretins. These effects may be of considerable importance in the treatment of postprandial hyperglycemia although they are not, strictly speaking, the result of a direct incretin effect on glucose metabolism.

KW - Glucose effectiveness

KW - Incretins

KW - Insulin action

UR - http://www.scopus.com/inward/record.url?scp=12244256810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12244256810&partnerID=8YFLogxK

U2 - 10.1055/s-2004-82617

DO - 10.1055/s-2004-82617

M3 - Article

VL - 36

SP - 830

EP - 836

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 11-12

ER -